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Abstract
Objective: Among older children, sleep‐disordered breathing (SDB) is associated with
measurable neurocognitive consequences. However, diagnostic SDB thresholds are
lacking for infants < 12 months. We sought to evaluate the relationship between SDB
indices, gestational age (GA), and postmenstrual age (PMA) for infants who
underwent clinically‐indicated polysomnograms at a tertiary care center.
Methods: Every infant < 3‐months chronological age whose first clinically‐indicated
polysomnogram was between 2/2012 and 2/2017 was included. Linear regression
was used to evaluate associations between apnea‐hypopnea index (AHI), obstructive‐
apnea index (OAI), and GA and PMA for infants with and without obvious clinical risk
factors for SDB (eg, micrognathia and cleft palate).
Results: For 53 infants without obvious SDB risk factors (GA 35.6 ± 4.5 weeks; PMA
41.2 ± 4.0 weeks), mean AHI was 27 ± 18 and OAI 2.9 ± 4.5. There was a weak inverse
relationship between AHI and PMA (r2 = 0.12, P = 0.01), but AHI was not predicted by
GA (r2 = 0.04, P = 0.13). Conversely, OAI was more strongly associated with GA
(r2 = 0.33, P < 0.0001) than PMA (r2 = 0.08, P = 0.036). For 28 infants with congenital
structural anomalies that predispose to SDB (GA 38.0 ± 3.1 weeks, PMA 43.1 ± 3.3
weeks, AHI 37.7 ± 30, OAI 8.2 ± 11.8), neither AHI nor OAI were related to PMA or
GA.
Conclusions: Among infants who received clinically‐indicated polysomnograms but
did not have obvious structural risk for SDB, AHI declined with advancing PMA, but
obstructive‐apnea was best predicted by prematurity. In contrast, the SDB risk did
not improve with increasing GA or PMA for infants with congenital structural risk
factors; such infants may not outgrow their risk for SDB.
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1 | INTRODUCTION
Sleep is a powerful indicator of global neurological function; a recent
study of neonates with risk for cerebral dysfunction reported that
objective sleep measures may independently predict 18 to 22‐month
neurodevelopmental outcomes.1 Healthy full‐term neonates have
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higher frequency of apneas and hypopneas than older children (mean
neonatal apnea‐hypopnea index, AHI, was reported to be 14.9 ± 9.1
among 30 healthy infants,2 with neonatal obstructive AHI 2.3 ± 2.5,
while obstructive AHI > 1 is considered abnormal for children > 12
months of age).3,4 Despite clinical observations of sleep‐disordered
breathing (SDB) patterns on polysomnography, parameters to guide
clinically appropriate diagnostic limits for SDB are not currently well‐
defined for neonates or infants < 1 year.5
Infants who are born prematurely are predisposed to adverse
cognitive outcomes6 and appear to be at risk for later SDB.7 Habitual
snoring with associated arousals, even in the absence of measurable
sleep apnea, among infants is associated with suboptimal motor
developmental scores.8 This suggests that the impact of even mild or
subthreshold severity symptoms of SDB may be clinically significant.
As symptoms of SDB are associated with later neurobehavioral
consequences,9 and are potentially treatable, establishing threshold
definitions for SDB in infants should be a priority for clinicians and
researchers. To begin to fill this important knowledge gap, we sought
to evaluate the relationship between SDB indices and gestational age
(GA) at birth and postmenstrual age (PMA) at the time of the
polysomnogram for infants at a tertiary care center.
We hypothesized that premature infants without structural
airway abnormalities would have higher AHI than term infants,7
but that their risk for SDB would decline with increasing PMA. The
risk for SDB may decline as the infant grows due to reduction in
chest wall compliance and developmental maturity of respiratory
control. Central sleep apnea indices have been observed to decline
over time in healthy term infants.10 Thus, we also expected an
inverse relationship between central apnea index (CAI) and PMA in
this cohort.
Secondarily, we predicted that infants with congenital structural
airway anomalies would have higher obstructive‐apnea indices (OAI)
than those without obvious risk factors, while infants with suspected
or confirmed genetic syndromes (which often impact central
respiratory drive and may be associated with hypotonia) would have
higher CAI and risk for hypoventilation than nonsyndromic infants.
We anticipated that all neonates would have declining SDB indices
with increasing PMA.
2 | METHODS
This study was approved by our Institutional Review Board and a
waiver of informed consent was granted.
Subjects: all infants of chronological age < 3 months who under-
went their first clinically‐indicated, attended polysomnogram be-
tween 2/2012 and 2/2017 at Michigan Medicine were included. Data
were abstracted via systematic medical record review and included
GA, PMA at time of the first polysomnogram, sex, birthweight, Apgar
scores, medical comorbidities, indication for polysomnography,
standard polysomnographic results, SDB‐related diagnoses, and
treatment or interventions recommended after the polysomnogram.
Infants who were predisposed to SDB due to suspected or confirmed
genetic or craniofacial abnormalities, structural airway abnormalities,
known structural brain abnormalities, such ventriculomegaly, or a
diagnosed congenital nervous system malformation, were analyzed
as a subgroup.
Exclusion criteria were as follows: patients who had undergone
polysomnography solely for research (not due to clinical suspicion for
SDB), incomplete information about the patient's gestational age at
birth in the medical record, patients whose first polysomnogram was
performed at a different institutions.
Polysomnography: attended polysomnography at our institution
includes six channel electroencephalography (F3/F4, C3/C4, and O1/
O2 electrode positions), two electrocardiogram channels, electro‐
oculogram, chin surface electromyography (EMG), bilateral anterior
tibialis EMG, chest and abdominal excursion, nasal pressure, nasal/
oral airflow (with thermal detection), a snoring sensor, oxygen
saturation by pulse oximetry, and transcutaneous carbon dioxide
monitoring. Video monitoring was recorded simultaneously. Clinical
polysomnography software was used (Compumedics, Victoria,
Australia). Sleep‐wake stage scoring was performed based on a
combination of behavioral observation and recorded polysomnogra-
phy data, according to contemporaneous standard neonatal scoring
rules.11,12 Studies before July 1, 2015 scored sleep‐wake stages by
30‐second epochs as wakefulness, quiet, active, or indeterminate
sleep.11 Subsequent studies were scored using the 2015 scoring
criteria by 30‐second epochs of wakefulness, nonrapid eye move-
ments (NREM; analogous to quiet sleep), REM (analogous to active
sleep), and transitional sleep (analogous to indeterminate sleep).12
Respiratory event scoring rules followed published pediatric
criteria.13 Obstructive‐apnea was defined as > 90% decrement in
airflow for the duration of at least two breaths with preserved
respiratory effort. Central apnea was identified by absence of
inspiratory effort and one of the following: duration > 20 seconds;
duration of two or more breaths and associated arousal or > 3%
oxygen desaturation; duration of at least two breaths and associated
heart rate < 50 beats per minute for at least 5 seconds or < 60 beats
per minute for at least 15 seconds. Hypopneas were scored based on
peak signal excursion decrement of > 30%, lasting at least two
breaths, and associated with at least one of a ≥ 3% oxygen
desaturation or an arousal. Hypopneas were not further classified
into central hypopneas or obstructive hypopneas. The apnea‐
hypopnea index (AHI) was calculated as the total number apneas
and hypopneas per hour of sleep. The obstructive‐apnea index (OAI)
included only obstructive apneas, while the central apnea index (CAI)
included only central apneas per hour of sleep; neither of these
subindices included hypopneas. Time spent with oxygen
saturation < 90% was calculated from valid pulse oximetry reading
during sleep, excluding movement artifact. Hypoventilation was
scored
when > 25% of the total sleep time was spent with carbon dioxide
monitoring > 50 mm Hg as measured by transcutaneous carbon
dioxide monitoring (TCO2). Given the lack of established thresholds
for infants, a diagnosis of obstructive sleep apnea was provided at
the discretion of the interpreting provider; the diagnosis was
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typically assigned when the OAI was higher than 1. Similarly, a
diagnosis of central sleep apnea was provided at the discretion of the
interpreting provider when the central apnea index was more than 5.
Primary central sleep apnea of infancy is defined by the ICSD‐3
(International Classification of Sleep Disorders, third edition) as
apnea or cyanosis noted by an observer or sleep‐related central
apnea or oxygen desaturation detected by monitoring in an infant at
least 37 weeks’ gestation, with PSG demonstrating either recurrent
episodes of central apneas > 20 seconds or periodic breathing for 5%
of the sleep time, not better explained by another disorder or by
medication.14 All polysomnograms were scored by an experienced,
registered polysomnographic technologist, and reviewed by a board‐
certified pediatric sleep medicine physician.
Analyses: multivariate regression was used to analyze associations
of GA and PMA with polysomnogram data including AHI, OAI, CAI,
percentage of time with baseline oxygen saturation (%O2) < 90%, and
diagnosis of hypoventilation. Fisher exact test was performed to
compare categorical groups of infants with specific SDB diagnoses.
One‐way analysis of variance (ANOVA) tests and Kruskal‐Wallis tests
for normal and skewed distributions, respectively, were used to
compare the polysomnographic data among groups of infants with
SDB diagnoses. Analyses were performed using SAS (Cary, NC).
3 | RESULTS
Among the 124 unique infants included in the initial chart review,
five were excluded due to lack of documented GA at birth and one
was excluded due to an outlier AHI value (136). Among the remaining
118 infants (Table 1), indications for polysomnography included:
apneic episodes (53), oxygen desaturation (43), suspected, or
diagnosed upper airway anomaly (eg, laryngomalacia and Pierre
Robin sequence) (31), apparent life‐threatening event or brief
resolved unexplained event (ALTE/BRUE) (16), cyanotic events (10),
noisy breathing or snoring (10), hypotonia (7), respiratory failure/
tracheostomy (7), and clinical hypoventilation (4) (Figure 1). Note
that some infants had more than one indication for their first
polysomnogram.
Diagnoses derived from the polysomnograms included obstruc-
tive sleep apnea (OSA) (67), central sleep apnea (CSA) (47), primary
central apnea of infancy (24), and hypoventilation (21). Recom-
mended treatments included clinic follow‐up (77), repeat PSG (70),
oxygen therapy (67), medication (58: caffeine, ranitidine, or proton
pump inhibitor), and surgery (35: eg, distraction osteogenesis,
tracheostomy, supraglottoplasty, and vallecular cyst removal).
Among the 118 infants (Table 1), 53 had no obvious risk factors
for SDB (GA 35.6 ± 4.5 weeks; PMA 41.2 ± 4.0 weeks) and their mean
AHI was 27 ± 18 and OAI 2.9 ± 4.5. There was a weak inverse
relationship between AHI and PMA for this group of infants
(r2 = 0.12, P = 0.01) (Figure 2D), but AHI was not predicted by GA
(r2 = 0.04, P = 0.13) (Figure 2C). Conversely, OAI was much more
strongly associated with GA (r2 = 0.33, P < 0.0001) (Figure 2A) than
PMA (r2 = 0.08, P = 0.036) (Figure 2B). Clinical variables including
birthweight (P = 0.79), sex (P = 0.53), and 5‐minute Apgar score
(P = 0.11) were not associated with AHI.
There were 28 infants with structural airway anomalies: isolated
cleft lip/palate (8), Pierre Robin Sequence (7), other structural
abnormalities (7: eg, laryngomalacia and micrognathia), and combina-
tion of an airway abnormality and a genetic abnormality (6).
Henceforth, this group of 28 infants will be labeled the “airway”
group. In addition, there were 31 infants with a confirmed or
suspected genetic syndrome, termed the “genetic” group. Genetic
diagnoses included pathological mutation in PHOX2B gene (1),
congenital myotonic dystrophy (1), DiGeorge syndrome (4), trisomy
21 (2), trisomy 18 (3), spinal muscular atrophy (2), Prader Willi (2),
VACTERL syndrome (vertebral defects, anal atresia, cardiac defects,
trachea‐esophageal fistula, renal anomalies, and limb abnormalities)
(1), Beckwith‐Wiedemann (1), Rubinstein‐Taybi (1), Cri‐du‐chat (1),
pathological MECP2 variant (1), Kabuki syndrome (1), myopathy (1),
and various chromosomal deletion syndromes (1p36, 7q21.11, 14q,
15q11, and 16p13.11), duplications (1q44, 8, 20), along with
suspected syndromes by facial dysmorphism or other multiorgan
anomalies suspicious for genetic syndrome. Six additional infants
were included which were assessed to have predisposing risk factors
for SDB yet did not fit cleanly into the other groups: myelomeningo-
cele, grade III‐IV intraventricular hemorrhage, hydrocephalus status‐
post implantation of ventriculo‐peritoneal shunt, and bronchopul-
monary dysplasia. Among the 28 patients in the “airway” group (GA
38.0 ± 3.1 weeks, PMA 43.1 ± 3.3 weeks, AHI 37.7 ± 30, OAI
8.2 ± 11.8), neither AHI nor OAI were related to PMA or GA.
Neither GA nor PMA was associated with oxygen desaturation
(percent of time with oxygen saturation < 90%) in the full sample, nor
in the “no obvious risk factors,” “airway,” or “genetic” subgroups
(Table 2). However, the percent of time with oxygen saturation < 90%
varied significantly among the subgroups (ANOVA P = 0.006), with
less time with oxygen saturation < 90% among infants without clear
SDB risk factors compared with the “airway” (P = 0.001) and “genetic”
(P = 0.001) subgroups (Table 1).
Likewise, neither CAI nor hypoventilation were associated with GA
or PMA in any of the groups (Table 2). Compared with the infants
without SDB risk factors, the proportion of infants with hypoventilation
was higher among the “airway” group (Fisher exact test P = 0.006) and
those with genetic diagnoses (P < 0.0001). CAI varied among patient
groups (ANOVA P = 0.01). Infants without obvious SDB risk factors had
higher CAI than those with genetic diagnoses. OAI did not vary among
the three groups of infants (ANOVA P = 0.51).
4 | DISCUSSION
These study results suggest that the natural history of SDB may
change during the first months of life. Among infants without obvious
predisposing risk factors for SDB, advancing PMA (eg, evolving
maturity after birth) was associated with lower AHI. However,
prematurity alone (low GA) did not predict AHI in the first 3 months
after birth.
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AHI is calculated by combining both obstructive and central apneas
into one calculation, but risks for each appear to be separate. We
demonstrate a strong inverse association between OAI and GA, while
the relationship between OAI and PMA is much less robust. These
findings suggest that infants born prematurely (low GA) have static risk
factors for obstructive respiratory events which do not correct with
evolving maturity. However, risk for SDB did not change with
prematurity or postnatal age among infants with predisposing structural
or genetic factors. For these subgroups of infants, the protective factors
of advancing age (PMA) and developmental status may be masked by
the SDB risk conferred by their congenital risk abnormalities. Thus, their
SDB risk may not be simply outgrown over time. This set of novel
findings has direct implications for SDB treatment: interventions may be
appropriate sooner for children with structural or genetic SDB risk
factors than for those without obvious anomalies as the former group is
unlikely to outgrow their SDB with watchful waiting.
Early treatment for SDB may be particularly important for
neurodevelopmental outcomes. Snoring was not directly assessed in
our study but is a risk factor for SDB. Parent‐reported snoring in the
first 4 weeks of life predicts snoring at 6 months of age.15 Even the
TABLE 1 Clinical and demographic data for 118 infants aged < 3 months who had a clinically‐indicated polysomnogram. Data are provided as
mean ± standard deviation unless otherwise indicated
Characteristics Total
No obvious risk
for SDBd
Airway
anomaliesa
Genetic
diagnosisb Otherc p‐value
N 118 53 28 31 6
Gestational age at birth (wk) 36.8 ± 3.9 35.6 ± 4.5 38.0 ± 3.1 37.5 ± 2.5 37.2 ± 4.9 P = 0.06
PMAd at time of PSGd (wk) 42.5 ± 3.9 41.2 ± 4.0 43.1 ± 3.3 44.2 ± 3.6 42.7 ± 4.8 P = 0.0065
Chronological age at time of PSG
(d)
40.4 ± 26.8 39.5 ± 26.5 35.7 ± 24.4 46.6 ± 27.1 38.3 ± 39.2 P = 0.46
Birthweight (kg) 2.8 ± 1.0 2.7 ± 1.0 3.1 ± 0.9 2.8 ± 0.8 3.2 ± 1.3 P = 0.25
Gender (F) # (%) 61 (52%) 27 (51%) 13 (46%) 18 (58%) 3 (50%) P = 0.85
5‐min Apgar score ‐ median
[interquartile range]
9 [1.25] 9 [1] 8 [1.25] 8 [2] 7.5 [1.75] P = 0.37
Total sleep time (TST) (min) 374.27 ± 83.9 378.8 ± 81.2 351.6 ± 63.9 349.9 ± 76.3 439.7 ± 148.7 P = 0.04
% REM (of TST) 37.5 ± 18.3 36.5 ± 18.2 38.2 ± 18.8 29.3 ± 14.6 42.4 ± 18.2 P = 0.14
% NREM (of TST) 59.4 ± 20.8 57.9 ± 21.9 56.5 ± 21.6 66.0 ± 17.1 53.0 ± 20.7 P = 0.21
AHId 31.5 ± 27.0 27.7 ± 18.7 37.7 ± 30 32 ± 36.1 33.0 ± 19.2 P = 0.48
AHI N (%) per group:
3‐5 4 (3.4%) 2 (3.8%) 0 (0%) 2 (6.5%) 0 (0%)
5‐10 16 (13.6%) 6 (11.3%) 5 (17.9%) 5 (16.1%) 0 (0%)
10‐20 38 (32.2%) 17(32.1%) 5 (17.9%) 14 (45.2%) 2 (33.3%)
20‐30 13 (11.0%) 8(15.1%) 3 (10.7%) 1 (3.2%) 1 (16.7%)
30‐40 11 (9.32%) 7 (13.2%) 2 (7.1%) 2 (6.5%) 0 (0%)
> 40 36 (30.5%) 13 (24.5%) 13 (46.4%) 7 (22.6%) 3 (50.0%)
OAId 4.7 ± 8.4 2.9 ± 4.5 8.2 ± 11.8 4.8 ± 9.6 3.1 ± 4.9 P = 0.51
CAId 7.2 ± 10.96 8.4 ± 11.6 5.3 ± 7.8 6.4 ± 12.9 10.0 ± 7.0 P = 0.01
Hypopnea index 19.8 ± 22.2 16.8 ± 14.6 25.3 ± 24.5 19.9 ± 29.8 19.9 ± 21.9 P = 0.72
%O2 < 90% 7.8 ± 14.3 3.0 ± 5.3 11.3 ± 16.7 13.0 ± 20.9 12.0 ± 10.3 P = 0.0062
Hypoventilation diagnosis (%) 21 (17.8%) 1 (1.8%) 6 (21.4%) 13 (41.9%) 1 (16.7%) airway > no risk
P = 0.006
genetic > no risk
P < 0.0001
Note: AHI is calculated as total apneas + hypopneas divided by total sleep time. OAI is calculated by obstructive apneas divided by total sleep time. CAI is
calculated by central apneas divided by total sleep time.
aAirway anomalies included cleft palate, Pierre Robin syndrome, respiratory failure with tracheostomy placement, glossoptosis, retrognathia,
micrognathia, and laryngomalacia.
bGenetic syndromes included central congenital hypoventilation syndrome, spinal muscular atrophy, congenital myotonic dystrophy, trisomy 18, trisomy
21, Prader Willi, Beckwith‐Widemann, Rubinstein‐Taybi, and pathogenic variant in MECP2 gene.
cIncluded those at risk for SDB, for example, myelomeningocele, grade III‐IV intraventricular hemorrhage and hydrocephalus s/p VP shunt,
bronchopulmonary dysplasia.
dAHI, apnea‐hypopnea index; CAI, central apnea index; OAI, obstructive‐apnea index; PMA, postmenstrual age; PSG, polysomnogram; SDB, sleep‐
disordered breathing.
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presence of snoring‐related arousals without demonstrable eleva-
tions in AHI (AHI < 1) has been associated with reduced Bayley
scores in infants.8 Snoring is commonly understood to fall along the
same disease spectrum as obstructive sleep apnea.16 Although
abnormal AHI thresholds have not yet been determined in infants,
it is hypothesized based on adult data that a higher AHI may
correlate with a higher disease burden. How a highly elevated AHI
(or OAI, CAI), as was observed in our study, even in infants without
obvious risk factors for SDB, may correlate with risk for abnormal
neurodevelopmental outcomes is currently uncertain. This is an
important target for future research.
In a study of 30 healthy, term infants who had PSGs at a
chronological age of less than 30 days, mean AHI was 14.9 ± 9.1 and
both CAI (5.4 ± 6.2) and OAI (2.3 ± 2.5) were much higher than
established normal thresholds for children older than 12 months.2
While results from a limited sample of healthy neonates cannot be
translated directly into diagnostic threshold recommendations, espe-
cially for infants with medical complexity, the data provide additional
evidence that standards for older children should not be extrapolated to
neonates. Comparing these results for normal infants with the findings
in our cohort suggests that neonates with medical comorbidities may
often have significantly elevated AHI, CAI, and OAI.
We report no associations between prematurity (low GA) or
postnatal development (PMA) and CAI, diagnosis of hypoventilation,
F IGURE 1 Indications for neonatal polysomnography for 118
consecutive infants < 3 months of age [Color figure can be viewed at
wileyonlinelibrary.com]
F IGURE 2 Among 53 infants without obvious risk factors for sleep‐disordered breathing, obstructive‐apnea index declined more robustly
with gestational age at birth (A, r2 = 0.33, P < 0.0001) than postmenstrual age (B, r2 = 0.08, P = 0.036). Conversely, apnea‐hypopnea index did not
vary with gestational age (C, r2 = 0.04, P = 0.13), but declined modestly with increasing postmenstrual age (D, r2 = 0.12, P = 0.01) [Color figure
can be viewed at wileyonlinelibrary.com]
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or oxygen desaturation (% O2 < 90%) within the first 3 months after
birth. This is in contrast to previous work that reported correlation
between rising PMA and lower CAI over the first 3 months of life
among healthy infants.10,17 By contrast, our study population was not
composed of healthy controls, but instead comprised of patients for
whom there was a clinical indication for polysomnography. In
addition, we did not have sufficient sample size of patients with
repeat polysomnograms to enable repeated evaluations over time.
Our patients may not have reached the PMA at which CAI might be
expected to decrease. Despite this, it is notable that oxygen
desaturation remained common even among the older infants in
our cohort; this may be a reflection of the clinical conditions that
triggered the request for polysomnography. In addition, the extent of
oxygen desaturation improves with age,18 yet the timing of the
polysomnography in our cohort may have been too early to
demonstrate an improvement with advancing age.
We confirm that infants with airway anomalies may be at
particularly high risk for OSA and oxygen desaturation. While CAI
was not more prevalent among infants with genetic syndromes than
the other groups, the risk for hypoventilation was especially elevated
for this subgroup. Though genetic syndromes are heterogeneous,
affected infants often have neonatal hypotonia, which may predis-
pose to clinical hypoventilation. Our data suggest that for such
infants, clinicians may need to focus particular attention on diagnosis
and management of hypoventilation.
PSG‐defined diagnoses of hypoventilation ( > 25% of the total
sleep time with CO2 values > 50 mm Hg) is well accepted. Yet, for
infants < 12 months of age, the thresholds for diagnosis of OSA, CSA,
and primary central apnea of infancy are not well‐defined. There is a
clear need to study the associations between neonatal OAI, CAI, and
outcomes to determine clinically‐meaningful diagnostic criteria and
to define thresholds for intervention.
Despite the lack of widespread consensus regarding the clinical
diagnosis of SDB in neonates, the results of the clinical polysomno-
graphy data reported here, combined with individual infants’ clinical
histories, triggered clinical interventions for all but nine infants (109/
118, 92%). The most common treatment was supplemental oxygen
(57%), but medication (caffeine, ranitidine, or proton pump inhibitor)
was prescribed for 49% and surgery was indicated for 30% (nearly all
of whom had congenital airway anomalies).
In contrast to older children, some respiratory events are
expected even among seemingly healthy infants. In one study of 37
healthy full‐term infants, the median AHI fell from 7.8 at 1 month to
4.9 at 3 months and CAI and percent time with oxygen saturation <
90% also declined.19 A limitation of that study is that unattended
home sleep apnea testing without EEG capability to detect sleep
staging or arousals was utilized, rather than gold‐standard attended
polysomnography. In a study of 1023 healthy term infants, median
OAI between 2 to 7 weeks was 0.3, with a declining frequency of
obstructive and mixed apneas as the infant was analyzed over time,
up to 27 weeks’ chronological age.20 These studies excluded
premature infants, and those with structural airway anomalies or
genetic syndromes. In contrast, our cohort instead represented a
tertiary care center referral base for clinical suspicion of SDB, which
included the infants which were excluded above. This is a likely
explanation for the apparently higher rate of polysomnographic
abnormalities among our study subjects.
Although we included every infant ≤ 3 months chronological age
who received a clinical, attended, gold‐standard polysomnogram
during a 5‐year timespan, our study has some limitations. The study
was retrospective and is subject to the inherent flaws of this design.
We are not able to comment on the natural history of polysomno-
graphic results for healthy newborn infants, since all of the included
patients had a clinical indication for a sleep evaluation. We did not
have a large enough sample of serial polysomnograms to permit
trajectory analyses of sleep data over time for individual infants and
the potential effect of night‐to‐night variability is unknown in this age
group. It is possible that infants with more severe disease presented
chronologically earlier than those with milder SDB.
TABLE 2 Bivariate analysis models of SDB risk for 118 infants < 3
months of age who had a clinically‐indicated polysomnogram
Characteristics Total
No obvious
risk
Airway
anomalies
N 118 53 28
AHI:
GA R2 = 0.0021
P = 0.62
R2 = 0.044
P = 0.13
R2 = 0.12
P = 0.07
PMA R2 = 0.070
P = 0.0037
R2 = 0.12
P = 0.01
R2 = 0.085
P = 0.13
OAI
GA R2 = 0.045
P = 0.021
R2 = 0.33
P < 0.0001
R2 = 0.076
P = 0.16
PMA R2 = 0.012
P = 0.23
R2 = 0.084
P = 0.036
R2 = 0.007
P = 0.66
CAI
GA R2 = 0.004
P = 0.48
R2 = 0.014
P = 0.40
R2 = 0.029
P = 0.39
PMA R2 = 0.012
P = 0.23
R2 = 0.0005
P = 0.89
R2 = 0.006
P = 0.70
% O2 < 90%
GA R2 = 0.0008
P = 0.80
R2 = 0.05
P = 0.11
R2 = 0.008
P = 0.65
PMA R2 = 0.005
P = 0.45
R2 = 0.067
P = 0.062
R2 = 0.036
P = 0.33
Hypoventilation
GA P = 0.80 Not valid* P = 0.37
PMA P = 0.21 Not valid P = 0.72
Abbreviations: AHI, apnea‐hypopnea index; CAI, central apnea index;
GA, gestational age; PMA, postmenstrual age; OAI, obstructive‐apnea
index; SDB, sleep‐disordered breathing.
Note: AHI is calculated as total apneas + hypopneas divided by total sleep
time. OAI is calculated by obstructive apneas divided by total sleep time.
CAI is calculated by central apneas divided by total sleep time.
*Not valid due to lack of sufficient sample in this group with diagnosis of
hypoventilation such that a linear regression could not be formed.
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5 | CONCLUSIONS
Despite the lack of established consensus regarding diagnostic
thresholds for SDB among infants, we demonstrated that polysom-
nography commonly triggers treatment for SDB in this age group.
Premature infants and those with structural airway anomalies and
genetic syndromes appear to have static risk factors for SDB for
which early intervention should be targeted; those with genetic
syndromes should also be closely monitored for hypoventilation.
These results highlight an urgent need for outcomes‐based research
on SDB in young infants to define diagnostic thresholds and enable
studies of therapeutic interventions.
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